In two phase 3 trials of 1399 adults and adolescents with severe alopecia areata, SALT ≤20 at week 24 was reached by 45.2%/44.6% on upadacitinib 15 mg and 55.0%/54.3% on 30 mg vs 1.5%/3.4% on placebo; serious adverse events 1.6%, 2.3% vs 0.4%.
RCTn = 1,399
Mostaghimi et al. Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Two Phase 3 UP-AA Randomized Clinical Trials